hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions

Acute Graft Versus Host Disease

Interventions

BIOLOGICAL

Human amniotic epithelial stem cells（hAESCs）

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)

BIOLOGICAL

placebo (cell preservation solution)

Same dose placebo (cell preservation solution) injections as control group

All Listed Sponsors

collaborator

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

INDUSTRY

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT06444022 - hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter